• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

Comparing Skincare OEM Quotations: Are Testing, Artwork, and Batch Release Included?

Two skincare OEM quotations can describe the same brief, use the same MOQ, and still differ in price by a wide margin — because they are rarely quoting the same scope. The gap usually…

Category: Body Care Sourcing Guides • Author: laeyo • Published: 2026-11-16 • Views: 14

Two skincare OEM quotations can describe the same brief, use the same MOQ, and still differ in price by a wide margin — because they are rarely quoting the same scope. The gap usually sits in three lines that are easy to leave out: product testing, artwork and label review, and batch release documentation. A quotation that excludes them is not necessarily cheaper; it is often just unfinished. This guide shows sourcing managers how to read a skincare OEM quotation line by line, what each line should actually include, and which evidence to request before signing.

It applies to body care and skincare SKUs — body lotion, body wash, body cream, hand cream, scalp and body serums — sold into the US, EU, UK, Australia or other cosmetic-route markets.

Why two quotations for the same brief rarely match

Before comparing numbers, confirm that both quotations describe the same deliverable. Most price differences come from scope, not from factory efficiency.

  • Specification version. A quote built on an early concept brief may not include the final spec, so tests are costed against a formula that will change.
  • Test ownership. Some factories quote formulation only and treat stability, microbiology and preservation testing as add-ons billed later.
  • Packaging route. Stock bottle plus label is priced very differently from a custom mold, and tooling amortization is often shown separately or hidden in unit price.
  • Artwork rounds. Unlimited artwork revisions versus two rounds is a real cost difference, and regulatory copy checking is frequently not included at all.
  • Documentation depth. A COA on a template is not the same as a full batch release package with spec version, method, release authorization and traceability.
  • Commercial terms. Incoterms, sample fees, retain sample storage and re-order pricing can shift the total cost more than the unit price suggests.

The three line items buyers forget to compare

1. Testing and substantiation

Testing is where quotations diverge most. Ask which tests are inside the unit price and which are invoiced separately, then confirm they are costed against the final formula version, not a lab prototype.

  • Stability: accelerated conditions plus ongoing real-time data. Request the protocol (temperatures, durations, test points, attributes monitored such as pH, viscosity, appearance, odor, package integrity) and the report format.
  • Microbiology: bulk and finished-product testing against the limits of the destination market, plus preservative efficacy testing where the formula is water-based.
  • Packaging compatibility: fill test with production bulk in production components — dose per actuation, leakage, vacuum or drop test, label adhesion, and interaction between fragrance or actives and plastic.
  • Claims substantiation: instrumental or clinical studies and consumer perception tests for any claim stronger than a cosmetic moisturizing statement.

If a quotation shows a single “testing” line with no breakdown, it is not comparable yet.

2. Artwork, labeling and claims guardrails

Artwork sits at the boundary between marketing and compliance, which is exactly why it falls through quotation gaps. Confirm in writing whether the factory performs a regulatory copy check on the label and what the output is.

  • Label review deliverable: a commented artwork file or review memo flagging ingredient naming, net content, warnings, batch and PAO marking, responsible person or address block, and language requirements per market.
  • Claims guardrails: each on-pack or web claim should map to a specific evidence record. Run this as a claim-to-evidence table with a claim ID, market, evidence ID, formula version, usage restrictions and regulatory status. No evidence ID, no artwork release.
  • Revision rounds: state how many are included and what triggers a re-quote.

3. Batch release and documentation handoff

Batch release is a controlled quality decision, not an automatic consequence of production finishing. A finished batch can pass every test and still be held pending review of deviations, out-of-specification or out-of-trend results, packaging records, line clearance and traceability.

  • Release states to expect: release, conditional release where procedures permit it, hold, reject or rework. Sales deadlines cannot override a quality hold.
  • Traceability chain: finished batch linked to bulk batch, formula and process version, line, raw material lots, packaging material lots, operators, QC results and micro results.
  • Retain samples: confirm they are taken, stored and retrievable for the retention period.

Quotation comparison table

Quotation line What “included” must mean Evidence to request Risk if excluded
Formulation and lab batch Costed against the approved brief and a named formula version Formula version ID, lab batch record, spec sheet draft Tests and pricing re-run after the formula changes
Stability Protocol-led accelerated and ongoing real-time testing on the final formula in the final pack Stability protocol and report, test points, acceptance criteria Viscosity, pH or emulsion drift discovered after launch
Microbiology and preservation Bulk and finished testing to destination-market limits plus preservative efficacy Micro report with limits, method, result and release status Batch held or recalled; repeat testing delays shipment
Packaging compatibility Fill test with production bulk in production components, not a water blank Compatibility report, dose per actuation, leak and drop results Pump mismatch, leakage, label lift, fragrance-plastic interaction
Artwork and label review Defined number of revision rounds plus a documented regulatory copy check Commented artwork file or review memo with open items closed Relabeling at your cost after print, or customs delay
Claims substantiation Study or consumer test allocated to each claim above basic cosmetic language Study protocol and report, claim-to-evidence mapping table Claim pulled from listing or packaging; refunds and relisting
Pilot run and scale-up Pilot batch on production equipment with in-process controls Pilot batch record, in-process check results, bulk yield Lab sample does not match production texture or fill behavior
Batch release documentation COA with spec version, method, acceptance criteria and release authorization COA, spec sheet, SDS, batch record extract, retain sample record Documents rejected by distributor or marketplace compliance review
Market registration support Named scope: responsible person, notification, dossier support per market Written scope statement listing which markets and which filings Product ready but not sellable in the target market

What a complete batch release package should contain

Use this as the acceptance test for the documentation line in any quotation. If the factory cannot show you a sample pack before you sign, treat the line as not included.

  • COA showing product, SKU, batch, manufacture date, applicable spec version, test items, results with units, specification and acceptance criteria, test method or internal method identifier, and quality release status with authorization.
  • Traceability record linking finished batch, bulk batch, formula and process versions, line, raw material and packaging lots, operators, QC and micro results.
  • Deviation and OOS/OOT status for the batch — open items must be visible, not summarized away.
  • Micro and stability records covering the released batch, plus the ongoing real-time program.
  • Packaging records including component lots, compatibility results and line clearance.
  • Retain sample confirmation with location and retention period.

One caution: a COA should never carry data that was not actually tested or cannot be traced to a method and a result. If a COA looks complete but cannot name its spec version, it is a template.

Red lines: what never to strip out to hit a price

  • Microbiology testing and preservative efficacy on water-based formulas.
  • Stability testing in the final pack, including packaging compatibility.
  • Batch release with a named spec version and an authorized quality sign-off.
  • Claim-to-evidence mapping before artwork release.
  • Traceability from finished batch back to raw material and packaging lots.

Compressing these moves cost from the quotation into launch risk, where it is far more expensive.

Copy-paste RFQ checklist

Share destination market(s) and sales channel for each SKU.
Confirm the formula version each test is costed against.
Provide the target retail price and first-order volume.
Attach packaging direction: stock, semi-custom, or custom mold.
Ask which tests are inside unit price and which are invoiced separately.
Request the stability protocol and test points before approval.
Confirm micro limits and preservative efficacy testing for the target market.
Request a packaging compatibility report from a production-bulk fill test.
Confirm how many artwork revision rounds are included.
Ask whether label regulatory copy review is included and what the output is.
Request the claim-to-evidence mapping template.
Confirm pilot run scope and in-process controls.
Request a redacted sample COA showing spec version and release authorization.
Request the batch traceability record format.
Confirm deviation and OOS/OOT disclosure at release.
Confirm retain sample storage and retention period.
Ask who owns the responsible person or notification role per market.
Confirm SDS and spec sheet delivery timing.
Lock Incoterms, sample fees and tooling amortization in writing.
Agree the documentation handoff date before the first shipment.
Review all open items in one written response before signing.

Common quotation traps and how to catch them

Trap 1 — Packaging compatibility tested on a water blank

  • Symptom: pump dispenses an inconsistent dose, product leaks in transit, or the label lifts after two weeks on shelf.
  • Root cause: compatibility was checked on a simple blank rather than the finished emulsion, and fragrance or actives interacted with the plastic or adhesive.
  • Prevention: require a fill test on production bulk with production components, with defined dose tolerance, leak, drop and adhesion checks.
  • What to request from factory: packaging compatibility report, component drawings and specs, dose-per-actuation data, adhesive and material declarations.

Trap 2 — Documentation that arrives after the goods

  • Symptom: the COA arrives without a spec version, method or release authorization, and the INCI on the label does not match the spec sheet.
  • Root cause: the COA is generated from a template at shipping time rather than from a controlled release decision.
  • Prevention: approve the COA and spec sheet templates before the pilot run, and make documentation handoff a release condition.
  • What to request from factory: redacted sample COA, controlled spec sheet with version number, SDS, and a written release workflow naming who signs.

Trap 3 — “Release” assumed because tests passed

  • Symptom: goods are booked for shipment while the batch is still on hold pending an open deviation.
  • Root cause: release was treated as automatic, and commercial pressure was allowed to precede the quality decision.
  • Prevention: ask for the batch status in writing before booking freight, and confirm who holds release authority.
  • What to request from factory: batch status statement (release, conditional, hold, reject), open deviation list, OOS/OOT status.

Trap 4 — Claims that outrun the evidence file

  • Symptom: “dermatologist tested” or a strength claim appears on artwork with no study behind it.
  • Root cause: copy was written before substantiation was scoped, and no one mapped claim to evidence.
  • Prevention: freeze claims before artwork, and require an evidence ID for each one.
  • What to request from factory: claim-to-evidence mapping table, study or consumer test protocols and reports, and written confirmation of what the formula can and cannot support.

Trap 5 — Lab sample that never becomes production reality

  • Symptom: production texture, color or fill behavior differs from the approved sample.
  • Root cause: no pilot run on production equipment, or the pilot ran without in-process controls.
  • Prevention: make the pilot batch the reference standard, and approve it against measured attributes rather than memory.
  • What to request from factory: pilot batch record, in-process check results, retained reference sample and its storage location.

Trap 6 — Stability treated as a post-launch activity

  • Symptom: separation, pH drift or viscosity change appears in market stock months after launch.
  • Root cause: stability was quoted but never scheduled, or run on a formula version that later changed.
  • Prevention: tie stability start date to formula lock, and require the report as a release input.
  • What to request from factory: stability protocol, interim and final reports, and the ongoing real-time testing commitment.

How to compare quotations in one working week

  1. Normalize the brief. Send every supplier the same spec version, packaging direction, market list and claim set.
  2. Split each quotation into three columns: included, excluded, and priced separately. Anything unmarked is treated as excluded.
  3. Request the evidence pack — sample COA, spec sheet, stability and micro report formats, packaging compatibility report, claim template — before commercial negotiation.
  4. Score scope, not price. A higher unit price with testing, artwork review and release documentation inside it is usually the lower total cost.
  5. Write the exclusions into the contract with an owner and a date for each.

FAQ

Should stability and micro testing be in the unit price or billed separately?

Either model works, provided the quotation states it explicitly and names the formula version the tests apply to. What matters is that the tests are scheduled, budgeted and treated as release inputs rather than optional extras added after the order is placed.

Who is responsible for label compliance — the brand or the factory?

The brand is the responsible party, but the factory should provide a documented regulatory copy review plus accurate technical inputs such as the ingredient list, concentration-relevant statements and usage instructions. Confirm in writing what the review covers and what it does not.

Is a COA proof that a batch was released?

Not on its own. A valid COA shows the batch was tested against a named specification version with results, methods, acceptance criteria and an authorized quality release status. Release also depends on closed deviations, no open out-of-specification results, and completed traceability and packaging record review.

Can we skip some testing to meet a launch date?

You can compress artwork rounds and pilot scheduling. Stability, microbiology, packaging compatibility and batch release documentation are not compressible without moving risk to the market. If a date is fixed, reduce SKU count or narrow the claim set instead.

Do we need separate testing for each destination market?

Often yes, at least for micro limits, labeling requirements and claim acceptability. The same product may be classified the same way across several cosmetic-route markets, but the finished-product evidence, label language and responsible-party details still need to be confirmed per market.

Informational only, not legal advice. Confirm regulatory classification and labeling requirements for each destination market with a qualified specialist.

Next step

If you want a quotation you can actually compare, send your destination markets, SKU list and formats, brand positioning, packaging direction and target launch date. Those five inputs let a manufacturer quote testing, artwork review and batch release documentation as visible lines instead of leaving them out — which is the only way a price comparison means anything.

Request a Quote

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).